Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rivoltini

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion moleculesF Arienti, C Gambacorti-Passerini, L Borin, et al.
European Journal of Immunology|May 16, 1998
Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patientsC Castelli, A Mazzocchi, F Rini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigensC Castelli, P Tarsini, A Mazzocchi, et al.
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Cancer Research|September 1, 1990
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumorsL Rivoltini, C Gambacorti-Passerini, M Squadrelli-Saraceno, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 5, 2000
Amino acid substitutions in the melanoma antigen recognized by T cell 1 peptide modulate cytokine responses in melanoma-specific T cellsM B Nielsen, A F Kirkin, D Loftus, et al.
The Journal of Experimental Medicine|July 1, 1994
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytesY Kawakami, S Eliyahu, K Sakaguchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 1995
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1M Sensi, C Traversari, M Radrizzani, et al.
Cancer Research|September 15, 1989
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activationC Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Biomed Research International|February 19, 2015
Melanoma cells homing to the brain: an in vitro modelA Rizzo, C Vasco, V Girgenti, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion moleculesF Arienti, C Gambacorti-Passerini, L Borin, et al.
European Journal of Immunology|May 16, 1998
Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patientsC Castelli, A Mazzocchi, F Rini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigensC Castelli, P Tarsini, A Mazzocchi, et al.
Tumori|December 31, 1991
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patientsS Spinazzé, S Viviani, P Bidoli, et al.
Cancer Research|September 1, 1990
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumorsL Rivoltini, C Gambacorti-Passerini, M Squadrelli-Saraceno, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 5, 2000
Amino acid substitutions in the melanoma antigen recognized by T cell 1 peptide modulate cytokine responses in melanoma-specific T cellsM B Nielsen, A F Kirkin, D Loftus, et al.
The Journal of Experimental Medicine|July 1, 1994
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytesY Kawakami, S Eliyahu, K Sakaguchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 1995
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1M Sensi, C Traversari, M Radrizzani, et al.
Cancer Research|September 15, 1989
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activationC Gambacorti-Passerini, L Rivoltini, M Radrizzani, et al.
Biomed Research International|February 19, 2015
Melanoma cells homing to the brain: an in vitro modelA Rizzo, C Vasco, V Girgenti, et al.
Pageof 9